<DOC>
	<DOCNO>NCT01540708</DOCNO>
	<brief_summary>The purpose study optimise device and/or formulation Fluticasone propionate ( FP ) /salmeterol ( SALM ) unit dose powder inhaler ( Rotahaler ) achieve drug delivery characteristic comparable Fluticasone propionate /salmeterol DISKUS inhaler . The indication asthma chronic obstructive pulmonary disease . The study open-label , randomise , cross-over , single centre study healthy volunteer conduct maximum 3 part , A , B C. The design adaptive pharmacokinetic ( PK ) data analysis follow part enable decision whether progression subsequent part require . Part A study test alternative version Rotahaler low airflow resistance . The study test one following option depend outcome part A . If progress , part B test modify Rotacap formulation include : ( 1 ) modify blend formulation , ( 2 ) reduce capsule fill weight , ( 3 ) different capsule type . Part B also test version Rotahaler intermediate airflow resistance . Part C test lower strength FP/salmeterol ( 100/50 mcg low ) and/or new unit dose DPI device ( BUDI ) . A total 36 subject enrol part ensure 32 complete . In cross-over arm , subject administer 7 dos ( 3.5 day bid ) PK sample follow administration 7th dose . A three-day minimum wash-out period separate cross-over arm .</brief_summary>
	<brief_title>A Single Centre Study Healthy Volunteers Optimise Rotacap Formulation ROTAHALER Device Delivery Fluticasone Propionate/Salmeterol</brief_title>
	<detailed_description>BACKGROUND : Asthma chronic inflammatory disease airway characterise vary recur symptom shortness breath , chest tightness , wheeze cough , airflow obstruction , bronchial hyper-responsiveness underlying inflammation . The GINA guideline [ Global Initiative Asthma , ( GINA ) update 2009 ] highlight need treat airway inflammation asthma recognise importance inhale prophylactic medication inhale corticosteroid combination Inhaled Corticosteroids ( ICS ) / Long Acting Beta Agonists ( LABA ) SERETIDE™ treatment chronic asthma . Chronic obstructive pulmonary disease ( COPD ) preventable treatable disease characterise airflow limitation fully reversible [ Celli , 2004 ] . The airflow limitation COPD primarily due small airway disease parenchymal destruction associate abnormal inflammatory response lung , mainly cause cigarette smoking [ Celli 2004 ] . COPD characterise symptom chronic progressive breathlessness ( dyspnea ) , cough sputum production major cause disability anxiety associate disease . The GOLD ( Global Strategy Diagnosis , Management Prevention Chronic Obstructive Pulmonary Disease ) guideline COPD state goal pharmacologic therapy control symptom , improve health status exercise tolerance , reduce frequency COPD exacerbation [ GOLD , 2008 ] . Research indicate inhale corticosteroid ( ICS ) combine long acting β2-agonist ( LABA ) effective individual component manage stable COPD reduce exacerbation improve lung function health status [ Ferguson , 2008 ; Calverley , 2007 ; Kardos , 2007 ] . The efficacy combination product , SERETIDE establish meter dose inhaler ( MDI ) multidose powder inhaler ( Ddpi ; DISKUS™/Accuhaler ) asthma Chronic Obstructive Pulmonary Disease , COPD variety dose strength . Alternative treatment option respect formulation SERETIDE mean delivery via inhaler device currently assess GSK view develop product bioavailability characteristic comparable SERETIDE deliver via multi-dose powder inhaler ( DISKUS™/Accuhaler ) . It intend product progress treatment administration asthma COPD patient . STUDY RATIONALE : A recently complete study , ASR114334 , [ GlaxoSmithKline document number YM2010/00082/02 ] evaluate comparative bioavailability fluticasone propionate/salmeterol deliver via establish multi-dose powder inhaler ( Ddpi , DISKUS/Accuhaler ) Rotahaler unit dose fluticasone propionate/salmeterol capsule-based powder inhaler ( Rdpi ) asthma COPD patient . The Rotahaler ( Rdpi ) inhaler airflow resistance similar DISKUS multi-dose inhaler ( Ddpi ) . Whilst active ingredient combination fluticasone propionate/salmeterol , device different respect handle instruction operation , although design deliver 250/50mcg bid dose strength ie mcg equivalent dos . The result show plasma exposure fluticasone propionate ( FP ) salmeterol 1.5 2 fold high follow repeat dose administration FP/salmeterol deliver Rdpi compare Ddpi , [ GlaxoSmithKline document number 2011N112456_00 ] . This observed asthma COPD patient . The purpose study , ASR116409 optimise device and/or formulation FP/salmeterol unit dose powder inhaler achieve drug delivery characteristic comparable FP/salmeterol DISKUS . DOSE RATIONALE : Two dos FP/salmeterol administer study : 250/50 mcg 100/50 mcg low , dose approve treatment asthma . These dos administer healthy subject maximum approved dos FP salmeterol indicate chronic therapy asthma ; therefore anticipate safety concern associate plan short term ( 3.5 day bid ) dose healthy subject . STUDY DESIGN : The study open-label , randomise , cross-over , single centre study healthy volunteer 3 part , A , B C. It conduct adaptive design pharmacokinetic data analysis follow part enable decision whether progression subsequent part require . A total 36 subject enrol part ensure 32 complete . In cross-over arm , subject administer 7 dos ( 3.5 day bid ) PK sample follow administration 7th dose . A three-day minimum wash-out period separate cross-over arm . Subjects may elect participate one part . Part A compare bioavailability characteristic follow GSK device : Ddpi ( multi-dose dry powder inhaler , DISKUS ) , Rdpi ( H ) ( capsule-based inhaler , high airflow resistance ) Rdpi ( L ) ( low airflow resistance ) . The Rdpi ( H ) high airflow resistance Ddpi compare Rdpi ( L ) could allow close PK match . Part A consist four treatment cross-over sub-study follow arm , arm replicate twice subject . Treatment arm part A comprise : - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 250/50mcg ) deliver via Ddpi - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 250/50mcg ) deliver via Rdpi ( H ) . Instructions subject take 2 steady , deep inhalation . - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 250/50mcg ) deliver via Rdpi ( L ) . Instructions subject take 1 fast deep inhalation - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 250/50mcg ) deliver via Rdpi ( L ) . Instructions subject take fast deep inhalation powder remain inhaler . The Rdpi ( H ) device ( 250/50mcg FP/salmeterol ) assess Part A bridge data back previous study ( ASR114334 ) show whether possible replicate 1.5 2 fold systemic exposure ratio Rdpi ( H ) /Ddpi healthy subject compare patient see previous study ( ASR114334 ) . Subjects dose twice daily 3 day fourth day morning . The first dose Day 1 administer site next four dos self-administered subject home . They attend Unit even 3rd day administer 6th dose remain Unit night follow day . They dose clinic ( 7th dose ) morning fourth day remain site completion 12 hour post-dose PK sample collection . Following 3-day minimum wash-out period last dose study medication ( Day 4 ) , subject participate subsequent arm Part A complete 4 arm twice i.e . 8 period plan completion Part A. PK sample analyse review conclusion Part A . If PK equivalence FP SALM demonstrate Rdpi ( L ) Ddpi , Rdpi ( H ) demonstrate high non-equivalent PK systemic exposure compare Ddpi , Part C conduct . If PK equivalence demonstrate , Part B conduct . Part B : Study design Part B depend PK result Part A . Prior start part B , decision make sponsor team whether Rdpi ( H ) Rdpi ( L ) device use ; decision base PK data part A. FP/Salm 250/50mcg Ddpi include Part B control group . If plasma exposure FP SALM obtain Part A Rdpi ( H ) statistically high Dpi Rdpi ( L ) statistically low Ddpi , Part B ass two intermediate airflow resistance version Rdpi [ Rdpi ( IM ) ] and/or formulation change : - modify blend formulation - reduce capsule fill weight , - different capsule type If plasma exposure FP SALM obtain Rdpi ( H ) statistically high Dpi Rdpi ( L ) statistically high Ddpi , Part B ass formulation change use Rdpi ( H ) ; - modify blend formulation - reduce capsule fill weight , - different capsule type One variable assessed time open-label , randomize , cross-over manner comprise 2 3 arm separate 3-day minimum wash-out period . All comparison do DISKUS arm , order test bioequivalence . The sample size use replicate arm evaluate defined completion part A , adapt design sample size variability observe previous part study . Following PK data analysis variable , two variable may finally group combined assessment open-label investigation . Evaluation two intermediate high airflow resistance Rdpi device [ Rdpi ( IM ) ] formulation change conduct cross-over design . The inhalation instruction ( number type breath ) decide Part A complete . An additional arm whereby subject administer Ddpi also include comparison . Part C compare bioavailability parameter 2 dosage strength FP/salmeterol : 100/50 mcg , 250/50mcg , deliver Ddpi device/formulation show demonstrate bioequivalence Part A and/or Part B . Another GSK unit dose device development , BUDI inhaler , also evaluate comparative bioavailability characteristic dos . If PK data Part A demonstrate Rdpi ( L ) PK equivalent Ddpi 250/50 mcg dose , Part B conduct . We also test bovine capsule may need certain market Part C Part B conduct . The various arm Part C conduct concurrently time dose arm depend availability study medication , device capsule type . Part C therefore conduct two different point time : Part C1 consist 3 4-way cross-over sub-study follow arm : - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 250/50mcg ) deliver via Ddpi - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 100/50mcg ) deliver via Ddpi - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 100/50mcg ) deliver via device/formulation combination select Part A B - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 250/50mcg ) deliver via Bovine capsule ( part B perform ) . Part C2 perform require BUDI inhaler make available , cross-over sub-study follow arm : - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 250/50mcg ) deliver via Ddpi - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 100/50mcg ) deliver via Ddpi - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 250/50mcg ) deliver via BUDI Inhaler - Administration 7 dos ( 3.5 day bid ) FP/salmeterol ( 100/50mcg ) deliver via BUDI Inhaler . The inhalation instruction ( number type breath ) decide part A complete The option combine Parts C1 C2 evaluate accord : - availability BUDI Inhaler time Part C - PK result previous part ( variability could affect need replicate arm part C well ; , bovine capsule may already test part B ) . PRIMARY OBJECTIVES : - To select device formulation combination fluticasone propionate/salmeterol ( 250/50mcg low ) pharmacokinetic equivalence ( ratio 0.8 1.25 ) fluticasone propionate/salmeterol ( 250/50mcg ) deliver via Ddpi ( multi dose dry powder inhaler ) - To compare pharmacokinetic parameter fluticasone propionate/salmeterol ( 250/50mcg low ) deliver range device and/or formulation fluticasone propionate/salmeterol ( 250/50mcg ) deliver via Ddpi healthy volunteer . SECONDARY OBJECTIVES : - To determine pharmacokinetic equivalence select device/formulation combination fluticasone propionate/salmeterol administer low dose match fluticasone propionate/salmeterol administer 100/50mcg dose Ddpi - To assess PK characteristic BUDI inhaler contain 100/50mcg fluticasone propionate/salmeterol 250/50mcg fluticasone propionate/salmeterol . PRIMARY ENDPOINT : -Pharmacokinetic endpoint : Area plasma fluticasone propionate concentration-time curve dose interval ; maximum observed concentration fluticasone propionate salmeterol plasma concentration-time curve last day study treatment period ( Day 4 ) . SECONDARY ENDPOINT : -Pharmacokinetic parameter : time maximum observed concentration ; terminal phase rate constant ; terminal phase half-life fluticasone propionate salmeterol ) last day treatment period ( Day 4 ) . TREATMENT ASSIGNMENT : During Part A study , subject assign one four sequence report table ( 4x4 Williams design replicates ) accordance randomization schedule generate Quantitative Sciences , prior start study , use validate internal software . Sequence number Arm 1 . A B D C D A C B 2 . B C A D C D B A 3 . C D B A B C A D 4 . D A C B A B D C A indicate Ddpi , B indicate Rdpi ( H ) , C indicate Rdpi ( L ) fast deep inhalation , D indicate Rdpi ( L ) fast deep inhalation powder remain inhaler . Williams design , replicate , adopt subsequent optional part study , depend result obtain part A .</detailed_description>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>INCLUSION CRITERIA : A subject eligible inclusion study follow criterion apply : ALT , alkaline phosphatase bilirubin less equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Single QTc , QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one protocol approve contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential abstinent agree use one protocol approve contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception followup visit Capable give informed consent , include compliance study requirement restriction list consent form . BMI within range 18 35 kg/m2 ( inclusive ) . Able use inhaler device adequately train EXCLUSION CRITERIA : A subject eligible inclusion study follow criterion apply : Medical Condition Exclusions : Subjects current diagnosis history asthma , exclude childhood asthma discharge physician ( e.g. , FTIH risk bronchoconstriction unknown , compound specific risk bronchoconstriction ) . This must document subject 's medical note . Subjects current previous diagnosis COPD . This must document subject 's medical note . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive test HIV antibody . Pregnant female determine positive serum hCG test screen prior dosing . Lactating female . Subject mentally legally incapacitate . Unwillingness inability follow procedure outline protocol . Medical Exclusions : Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History sensitivity heparin heparininduced thrombocytopenia . Lifestyle Exclusions : A positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . History regular alcohol consumption within 6 month screen visit define follow Australian guideline : Males : An average weekly intake great 21 unit average daily intake great 3 unit . Females : An average weekly intake great 14 unit average daily intake great 2 unit . One unit equivalent 270 mL full strength beer , 470 mL light beer , 30 mL spirit 100 mL wine . Grapefruit , pummelo , grapefruit juice contain product exclude 2 week prior randomisation ( study part ) collection final blood sample Day 4 . Where participation study would result donation blood blood product excess 500 mL within 56 day period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Respiratory</keyword>
	<keyword>COPD</keyword>
</DOC>